Fierce Pharma Week 2026: 5 shifts changing how pharma reaches patients and doctors

More than 3,500 people filled the Pennsylvania Convention Center in Philadelphia for Fierce Pharma Week 2026 from September 14 to 17. That’s 21% more than last year.

AI was everywhere, as expected. But the tone had changed. Speakers talked less about what new tools might do. They focused on what makes them work: clean data, clear rules, and real trust with patients and doctors.

Here are five shifts that stood out, and what each one means for your commercial team.

1. AI moved from "wow" to "prove it"

Most pharma teams already use AI. The question in Philadelphia was how to use it safely at scale. Four needs kept coming up:

• Governance: Decide which AI tools staff may use, what data can go into them, who double-checks the results, and when a person must sign off.
• Compliance: Make sure AI use follows privacy laws and industry rules, including a careful review of any promo copy AI helps write.
• Accurate data: AI is only as good as what it learns from. Gaps or bias in your data turn into wrong answers.
• Change management: Teams need training on what AI can and can’t do.

Accuracy got its own spotlight. AI can sound sure of itself even when it’s wrong. That invites “cognitive surrender,” where people accept an AI answer without thinking it through.

Doctors aren’t immune. Even physicians with AI training can see diagnostic reasoning suffer when chatbot advice contains errors.

Rules are still catching up, even at the practices pharma markets to. Starting from established AI risk-management frameworks gives teams a practical foundation.

2. The real job is earning trust, not just awareness

The opening keynote paired Genentech CMO Zoë Lazarre with comedian Damon Wayans, who lives with type 2 diabetes. Their campaign, “AI Eyes on DME,” targets diabetic macular edema, a diabetes complication that can cause vision loss.

Genentech first saw this as an awareness gap. But conversations with patients showed that fear and stigma were holding people back, too. The campaign uses humor and everyday words to say “funny vision” instead of medical terms.

Trust is also shifting to AI. Many patients now get health information from AI tools and Google’s AI Overviews. Brands need to check how these tools describe them and fill gaps with clear, accurate content.

Meanwhile, the old awareness playbook is getting harder to run. Regulatory changes can make broadcast advertising more complex and costly.

3. "Patient-centric" is becoming "patient-driven"

Almost every drugmaker says it puts patients first. The message at Fierce Pharma Week was to push for something more concrete: patient-driven science.

The big change is timing. Patients shape the work from day one, not after a therapy already exists. That means first studying their real lives: the hurdles before a diagnosis, how treatment disrupts their days, and the outcomes they care about that standard trial measures miss.

Those insights should guide how trials are built, which programs move forward, what evidence gets gathered, how side effects are handled, and how the therapy reaches people.

Data turns this idea into a plan. Claims records and real-world data can show how long patients bounce between doctors before a diagnosis, or where they drop off treatment.

4. GLP-1s made awareness the easy part

Pharma marketing usually starts with building awareness. GLP-1s skipped that step, since people already know them from TV, social media, and friends. The work shifts to teaching, easing cost and coverage problems, and keeping people on treatment.

That support has to change over time. Early on, people need help sorting facts from hype before they see a doctor. Later, the questions turn to side effects, surprise bills, insurance denials, and how to manage doses.

Staying on therapy is the hardest part. Cost, follow-up care, and regular prescriber contact can strongly affect whether people continue treatment.

5. To reach the right doctors, map the organizations around them

More data and more channels haven’t made doctors easier to reach. If anything, they’re tuning out. Physicians say they’re buried in information and no longer have time for piles of emails or steak dinners.

Volume won’t fix this. Precision will. That starts with three questions: Which providers matter most for your therapy? Which patients do they see? Who do they work with? The answers tell you what to say and what to do next.

We’d add one more layer: the organization. Hospital employment, private equity ownership, payer relationships, care pathways, and control structures all influence which drugs make formularies and which doctors can prescribe them.

This context also ties your doctor and patient efforts together. When you know which providers treat the patients you want to reach, your messages to each group can support each other instead of competing.

That’s what Intent.Health is built for. We map the hierarchies inside health systems so commercial teams can find the people who actually decide, with data refreshed in near real time.

The bottom line

Fierce Pharma Week 2026 showed an industry done chasing shiny tools. AI needs guardrails and clean data. Patients want honesty and steady support. Doctors want fewer, better conversations. The teams that win will know exactly who they’re talking to, from the waiting room to the formulary committee.

Map your target health systems